EFFECTS OF A NEW CARDIOTONIC AGENT, "TA-064", IN PATIENTS WITH DILATED CARDIOMYOPATHY : RELATIONSHIP BETWEEN CARDIAC EFFECT OF TA-064 AND SEVERITY OF MYOCARDIAL LESION

概要

論文の詳細を見る
In 18 patients with dilated cardiomyopathy (DCM), the effects of a new cardiotonic agent, TA-064, given in both consecutive and intermittent (3 days on, 11 days off) oral doses were studied for 3 months by echocardiography and endomyocardial biopsy. After 3 months of consecutive administration. 11 patients (61%) had improved symptomatically and the %US increased (p< 0.001) and LVDd decreased (p<0.05), but the other 7 patients had not improved. At the pretreatment state these 7 patients in whom Ta-064 was not effective had smaller %US (p<0.01) and larger LVDd (p<0.05) than the 11 patients in whom the drug was effective. The non-effective group also had more severe myocardial fibrosis (p<0.05) and cellular hypertrophy (p<0.01) than the effective group. After 3 months of intermittent administration in 10 patients in whom consecutive administration had been proved effective, 7 patients sustained symptomatic improvement and increased %US (p<0.01), but the other 3 patients did not sustain the improvement. The latter group had smaller %US, larger LVDd and more severe myocardial fibrosis than the former group at the pretreatment state. These results indicate that the effects of TA-064 are dependent on the severity of basal cardiac function and myocardial damage, and that in patients with milder DCM, the effects can be sustained by intermittent administration.
社団法人日本循環器学会の論文
1987-03-20